News



  • Valneva Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 20192019-01-16

    Valneva Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019

    Saint Herblain (France), January 16, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, confirmed today its revenue and product sales guidance for 2018 and provided initial product sales guidance for 2019.

    PDF Download
    auf Deutsch lesen
  • Valneva Announces New $59 Million IXIARO® Supply Contract with US Government 2019-01-16

    Valneva Announces New $59 Million IXIARO® Supply Contract with US Government

    Saint Herblain (France), January 16, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announced today the signing of a new $59 million contract with the U.S. government Department of Defense for the supply of its Japanese encephalitis (JE) vaccine IXIARO®.

    PDF Download
    auf Deutsch lesen
  • Valneva Announces its Intention to Delist from the Vienna Stock Exchange2019-01-07

    Valneva Announces its Intention to Delist from the Vienna Stock Exchange

    Trading will be centralized on Euronext Paris

    Saint-Herblain (France), January 7, 2019 – Valneva SE (“Valneva”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announced today that it intends to delist from the Vienna Stock Exchange (VSE) in order to focus on the best capital markets for life science companies and increase liquidity by centralizing trading on Euronext Paris.

    PDF Download
    auf Deutsch lesen
  • Valneva Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate2019-01-07

    Valneva Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate

    Phase 1 interim results showed an excellent immunogenicity profile after a single-shot vaccination and an acceptable safety profile, supporting further development
    • 100% seroconversion rate achieved at Day 28 after a single-shot vaccination in a pooled analysis of all dose groups
    • Pooled analysis showed a high antibody response based on geometric mean titre
    • No serious adverse events or adverse events of special interest were reported up to Day 28

    PDF Download
    auf Deutsch lesen
Please update your browser...